DEFLAZACORT Drug Patent Profile
✉ Email this page to a colleague
When do Deflazacort patents expire, and what generic alternatives are available?
Deflazacort is a drug marketed by Tris Pharma Inc and Aurobindo Pharma Ltd and is included in two NDAs.
The generic ingredient in DEFLAZACORT is deflazacort. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the deflazacort profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Deflazacort
A generic version of DEFLAZACORT was approved as deflazacort by AUROBINDO PHARMA LTD on February 9th, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEFLAZACORT?
- What are the global sales for DEFLAZACORT?
- What is Average Wholesale Price for DEFLAZACORT?
Summary for DEFLAZACORT
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 75 |
Clinical Trials: | 23 |
Patent Applications: | 5,782 |
DailyMed Link: | DEFLAZACORT at DailyMed |
Recent Clinical Trials for DEFLAZACORT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Parc de Salut Mar | Phase 1 |
FibroGen | Phase 3 |
Catabasis Pharmaceuticals | Phase 1 |
Pharmacology for DEFLAZACORT
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for DEFLAZACORT
US Patents and Regulatory Information for DEFLAZACORT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tris Pharma Inc | DEFLAZACORT | deflazacort | SUSPENSION;ORAL | 217813-001 | Apr 25, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Aurobindo Pharma Ltd | DEFLAZACORT | deflazacort | TABLET;ORAL | 217123-003 | Feb 9, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Aurobindo Pharma Ltd | DEFLAZACORT | deflazacort | TABLET;ORAL | 217123-001 | Feb 9, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Aurobindo Pharma Ltd | DEFLAZACORT | deflazacort | TABLET;ORAL | 217123-002 | Feb 9, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Aurobindo Pharma Ltd | DEFLAZACORT | deflazacort | TABLET;ORAL | 217123-004 | Feb 9, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |